Orsini, a specialty pharmacy known for its work in rare disease care, has been named a specialty pharmacy partner for LISRAYA (brepocitinib), a newly approved oral treatment from Priovant Therapeutics for adults living with dermatomyositis. The once-daily medication is notable as the first targeted therapy cleared for this rare and often debilitating autoimmune condition.
Dermatomyositis affects the skin and muscles, causing painful rashes and progressive weakness, and can extend to the lungs, heart, and digestive system. Because treatment options have historically been limited, the approval marks a meaningful shift for patients and their care teams.
LISRAYA’s approval is supported by findings from the VALOR trial, described as the largest placebo-controlled study conducted in dermatomyositis to date. Trial participants who received the therapy showed measurable improvement across several disease indicators, including muscle strength, skin symptoms, overall functioning, and the ability to reduce steroid use.
Orsini leadership expressed enthusiasm about supporting patients through this new option, framing the collaboration as an opportunity to ease access to a therapy long awaited by the dermatomyositis community. Priovant’s leadership echoed that sentiment, pointing to Orsini’s established track record with rare disease therapies as key to ensuring patients transition smoothly onto treatment.
Founded in 1987, Orsini specializes in connecting patients with advanced and rare disease therapies through pharmacy distribution, clinical support, patient services, and home infusion care. The company holds accreditation from ACHC, URAC, and NABP, including URAC’s Rare Disease Pharmacy Center of Excellence recognition.
LISRAYA carries a boxed warning covering risks of serious infection, mortality, malignancy, major cardiovascular events, and thrombosis. Prescribers and patients are advised to consult the full prescribing information before starting therapy.
Written By: Sayan Das
Graphics by: Pramit Hazra
